Coherent
COHR · NYSEOptical Instruments & Lenses · Fiscal year ends Jun 30
Coherent reported revenue of $7.1B in the fiscal year ended Jun 2026, up 22.5% from the year before. Net income was $805M. Operating cash flow of $80M less capital expenditure of $1.1B left free cash flow of −$1B. Net debt was $2.1B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | $3.3B | $5.2B | $4.7B | $5.8B | $7.1B |
| Cost of revenue | $2.1B | $3.5B | $3.3B | $3.8B | $4.4B |
| Gross profit | $1.3B | $1.6B | $1.5B | $2B | $2.7B |
| Research & development | $377M | $500M | $479M | $582M | $723M |
| Selling, general & admin | $474M | $1B | $854M | $926M | $1B |
| Operating income | $414M | −$37M | $96M | – | – |
| Interest expense | $121M | $287M | – | – | – |
| Pre-tax income | $282M | −$356M | −$148M | $94M | $848M |
| Income tax | $47M | −$96M | $11M | $64M | $61M |
| Net income | $235M | −$259M | −$156M | $49M | $805M |
| Diluted EPS | 1.45 | −2.93 | −1.84 | −0.52 | 4.12 |
| Diluted shares | 117M | 138M | 152M | 155M | 195M |
Balance sheet
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | $2.6B | $821M | $926M | $909M | $1.2B |
| Receivables | $700M | $902M | $849M | $964M | $1.3B |
| Inventory | $903M | $1.3B | $1.3B | $1.4B | $2.6B |
| Current assets | $4.3B | $3.3B | $3.7B | $3.9B | $6.9B |
| Net PP&E | – | – | – | $1.9B | $3B |
| Goodwill | $1.3B | $4.5B | $4.5B | $4.5B | $4.4B |
| Total assets | $7.8B | $13.7B | $14.5B | $14.9B | $18.3B |
| Payables | $435M | $405M | $632M | $847M | $1.9B |
| Deferred revenue | $23M | $104M | $62M | $63M | $48M |
| Current liabilities | $1.3B | $1.1B | $1.3B | $1.8B | $2.9B |
| Short-term debt | $403M | $75M | $74M | $188M | $8M |
| Long-term debt | $1.9B | $4.2B | $4B | $3.5B | $3.2B |
| Total liabilities | $3.5B | $6.5B | $6.5B | $6.4B | $7.1B |
| Shareholders' equity | $3.6B | $5B | $5.2B | $5.6B | $10.9B |
Cash flow
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Operating cash flow | $413M | $634M | $546M | $634M | $80M |
| Capital expenditure | $314M | $436M | $347M | $441M | $1.1B |
| Free cash flow | $99M | $198M | $199M | $193M | −$1B |
| Depreciation & amortisation | $287M | $682B | $560M | $554M | $522M |
| Stock-based compensation | $73M | $149M | $126M | $160M | $186M |
| Acquisitions | $0 | $5.5B | $0 | $0 | – |
| Share buybacks | $0 | – | – | – | – |
Key ratios
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 55.6% | −8.8% | 23.4% | 22.5% |
| Operating income growth (YoY) | – | −109.0% | – | – | – |
| EPS growth (YoY) | – | −302.1% | – | – | – |
| Gross margin | 38.2% | 31.4% | 30.9% | 35.2% | 37.5% |
| Operating margin | 12.5% | −0.7% | 2.0% | – | – |
| Net margin | 7.1% | −5.0% | −3.3% | 0.8% | 11.3% |
| Return on equityBlank when equity is negative | 6.5% | −5.2% | −3.0% | 0.9% | 7.4% |
| ROCEEBIT ÷ (assets − current liabilities) | 6.3% | −0.3% | 0.7% | – | – |
| Free cash flow margin | 3.0% | 3.8% | 4.2% | 3.3% | −14.4% |
| Cash conversion (CFO ÷ net income) | 1.76x | −2.44x | −3.49x | 12.8x | 0.10x |
| Receivable days | 77 | 64 | 66 | 61 | 69 |
| Inventory days | 161 | 131 | 144 | 139 | 212 |
| Payable days | 77 | 42 | 71 | 82 | 156 |
| Interest cover | 3.42x | −0.13x | – | – | – |
| Debt ÷ equity | 0.64x | 0.86x | 0.79x | 0.65x | 0.30x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | −$282M | $3.5B | $3.2B | $2.8B | $2.1B |
| Current ratio | 3.40x | 3.01x | 2.72x | 2.19x | 2.43x |
Recent filings
More in Optical Instruments & Lenses
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.